Argenica Therapeutics Ltd (AGN) - Total Liabilities
Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has total liabilities worth AU$1.76 Million AUD (≈ $1.24 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AGN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Argenica Therapeutics Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AGN total asset value.
Argenica Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Argenica Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM3.09 Million |
|
Magnum Mining and Exploration Ltd
AU:MGU
|
Australia | AU$1.11 Million |
|
Dolphin Entertainment Inc
NASDAQ:DLPN
|
USA | $48.64 Million |
|
Quoin Pharmaceuticals Ltd DRC
NASDAQ:QNRX
|
USA | $8.04 Million |
|
DeepMarkit Corp.
NASDAQ:MKTSF
|
USA | $778.36K |
|
Mont Royal Resources Ltd
AU:MRZ
|
Australia | AU$382.34K |
|
CMX GOLD+SILVER CORP.
F:6GS
|
Germany | €733.54K |
|
Sejin T.S Co.Ltd
KQ:067770
|
Korea | ₩1.08 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Argenica Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Argenica Therapeutics Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argenica Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argenica Therapeutics Ltd (2019–2024)
The table below shows the annual total liabilities of Argenica Therapeutics Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$3.80 Million ≈ $2.69 Million |
+56.66% |
| 2023-12-31 | AU$2.43 Million ≈ $1.72 Million |
+29.46% |
| 2022-12-31 | AU$1.87 Million ≈ $1.33 Million |
+154.71% |
| 2021-12-31 | AU$735.91K ≈ $520.70K |
+72.86% |
| 2020-12-31 | AU$425.72K ≈ $301.22K |
+18.50% |
| 2019-12-31 | AU$359.26K ≈ $254.20K |
-- |
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more